Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis

被引：0
作者：
Jiwon Oh
Paul W. O’Connor
机构：
[1] Johns Hopkins University,Department of Neurology
[2] University of Toronto,St. Michael’s Hospital, Division of Neurology, Department of Medicine
来源：
CNS Drugs | 2013年 / 27卷
关键词：
Multiple Sclerosis; Multiple Sclerosis Patient; Progressive Multifocal Leukoencephalopathy; Natalizumab; Glatiramer Acetate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Treatment options for relapsing-remitting multiple sclerosis (RRMS) have been continuously expanding in recent years, and the emergence of a number of oral disease-modifying agents (DMAs) has significantly changed the landscape of therapeutic options for MS patients. Many of these oral DMAs have demonstrated satisfactory safety and tolerability profiles in clinical trial settings, but the long-term safety of these agents is an important concern. This review discusses salient points on the safety and clinical efficacy of the approved and emerging novel oral therapies in RRMS, including fingolimod, teriflunomide, dimethyl fumarate, laquinimod, and cladribine.
引用
收藏
页码：591 / 609
页数：18
相关论文
共 294 条
[11]  
Quackenbush E(2012)Fingolimod and multiple sclerosis: four cautionary tales Neurology 79 1942-1943
[12]  
Xie J(1998)Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide Biochem J 336 299-303
[13]  
Milligan J(1995)The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis J Pharmacol Exp Ther 275 1043-1049
[14]  
Miron VE(1999)Mechanism of action for leflunomide in rheumatoid arthritis Clin Immunol 93 198-208
[15]  
Jung CG(1998)Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans J Biol Chem 273 21682-21691
[16]  
Kim HJ(2000)Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases Immunopharmacology 47 273-289
[17]  
Kennedy TE(1995)Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans: disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors J Biol Chem 270 29682-29689
[18]  
Soliven B(1998)Dose-dependent enhancing and inhibitory effects of A77 1726 (leflunomide) on cytotoxic T lymphocyte induction Int J Immunopharmacol 20 505-513
[19]  
Antel JP(2004)Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide–mechanisms independent of pyrimidine depletion J Leukoc Biol 76 950-960
[20]  
Kappos L(2000)Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis J Immunol 165 5962-5969
12345678910